Financials
Financial year 2025
Sapphire Pharmaceuticals (Europe) from Brugge, company number BE0649580096, closed financial year 2025 with a result of € -104,413 after tax. For that financial year Sapphire Pharmaceuticals (Europe) recorded a gross margin of € -68,177 and equity of € 26,802. Compared with financial year 2024, the result moved from € 275,738 to € -104,413. The company made a loss. The buffer shrank hard: equity is 80 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.
€ 26,802
▼ 80% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -104,413
▼ still € 275,738 profit in 2024
Profit after tax over the fiscal year.
€ 20,885
▼ 84% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -379,398.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 1,906
▼ 52% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 7,379
▲ € 6,410 vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -32,747 | € -45,245 | € 277,492 | € -68,177 | ▼ € 345,669 |
| Profit after taxes | € -35,297 | € -48,590 | € 275,738 | € -104,413 | ▼ € 380,151 |
| Equity | € -95,934 | € -144,523 | € 131,215 | € 26,802 | ▼ 80% |
| Total debts | € 190,137 | € 243,454 | € 131,258 | € 26,749 | ▼ 80% |
| Cash | € 26,304 | € 21,649 | € 127,461 | € 20,885 | ▼ 84% |
| Land & buildings | - | - | € 2,238 | € 2,122 | ▼ 5% |
| Retained profit | € -502,134 | € -550,723 | € -274,985 | € -379,398 | ▼ € 104,413 |
| Balance sheet total | € 94,203 | € 98,930 | € 262,473 | € 53,551 | ▼ 80% |
Key figures of Sapphire Pharmaceuticals (Europe), fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Sapphire Pharmaceuticals (Europe)?
What happened at Sapphire Pharmaceuticals (Europe) in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 104,413 (▼ € 380,151 vs 2024). filed late Source: NBB ↗
- New establishment in Brugge. KBO
- Stephen De Prêtre became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 35,297 loss in 2022 to € 104,413 loss in 2025.
Best year ever: 2024, with € 275,738 profit.
A new publication or filing at Sapphire Pharmaceuticals (Europe)? We notify you, reason included.
Follow Sapphire Pharmaceuticals (Europe)Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Sapphire Pharmaceuticals (Europe) is Stephen De Prêtre. Stephen De Prêtre is also behind ATLAS PHARMACEUTICALS.
Directors
According to the 2025 annual accounts
since 2016
Establishments
Establishment units
Physical locations of this company
De Linde 107
8310 Brugge
Jan Breydellaan 25
8200 Brugge
Active since 3 March 2016
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0649.580.096
- VAT number
- BE 0649.580.096
- Registered office
- De Linde 107, 8310 Brugge
- Names & denominations
- Sapphire Pharmaceuticals (Europe)
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 March 2016
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Groothandel in informatie- en communicatieapparatuur
Groothandel in andere kantoormachines en kantoorbenodigdheden, met uitzondering van computers en randapparatuur
Detailhandel in farmaceutische producten
Groothandel in chemische producten voor industrieel gebruik
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels